Stay updated on Pembrolizumab/Vibostolimab vs Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab/Vibostolimab vs Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab/Vibostolimab vs Pembrolizumab in Melanoma Clinical Trial page
- CheckyesterdayChange DetectedThe page’s interface revision was updated from v3.5.2 to v3.5.3, reflecting a maintenance/version change to the ClinicalTrials.gov site UI.SummaryDifference0.1%

- Check8 days agoChange DetectedThe record history shows a revision bump from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check37 days agoChange DetectedRevision v3.5.0 was added to the history and revision v3.4.3 was removed.SummaryDifference0.1%

- Check44 days agoChange DetectedRevision history now shows v3.4.3 added and v3.4.2 removed.SummaryDifference0.1%

- Check73 days agoChange DetectedAdded Revision: v3.4.2 to the history. The funding notice and Revision: v3.4.1 were removed.SummaryDifference0.4%

- Check80 days agoChange DetectedAdded a government funding lapse notice with operating status guidance and updated the page revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab/Vibostolimab vs Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab/Vibostolimab vs Pembrolizumab in Melanoma Clinical Trial page.